Midostaurin (** - Rydapt® (brand name) - Generic midostaurin **)
Other Medications
Description
Midostaurin is primarily used in the treatment of acute myeloid leukemia (AML) with FLT3 mutations and not typically indicated for colorectal cancer; it has shown efficacy when combined with chemotherapy in AML patients, but its role in CCR remains investigational.
Mechanism of Action
Midostaurin is a multi-targeted kinase inhibitor that inhibits multiple tyrosine kinases, including FLT3 and PKC, which are implicated in the proliferation of cancer cells; it also has anti-angiogenic properties by inhibiting VEGFR2.
Side Effects
Febrile neutropenia; thrombocytopenia; vomiting; nausea; diarrhea; fatigue; rash; edema; dyspnea
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT01282502
med_phase_prefix1
Archived
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
United States